Here are the 10-K annual reports from Jupiter Neurosciences, Inc. (JUNS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow JUNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JUNS filings page.
Jupiter Neurosciences, Inc. files its annual report describing a clinical-stage CNS drug pipeline built around its proprietary resveratrol formulation JOTROL™ and a new consumer wellness brand, Nugevia. The company is advancing a Phase IIa Parkinson’s trial and planning additional studies in mild cognitive impairment, Alzheimer’s disease and rare disorders such as MPS I and MELAS.
Jupiter raised $11 million in December 2024 via a Nasdaq-listed public offering and is pursuing Asian partnerships and out-licensing to support development. However, it has generated minimal product revenue to date, carries indebtedness, requires substantial additional capital, and discloses that management and auditors see substantial doubt about its ability to continue as a going concern.